Skip to main content

Table 5 NIS gene therapy in extrathyroidal neoplasia

From: Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer

Neoplasia Vector Combined treatments (*) Promoter (**) References
Neuroblastoma Plasmid-polyplex   CMV [88]
Medulloblastoma MV +   [89]
Glioma Ad   CMV [90]
Retrovirus   LTR [91]
Multiple myeloma MV +   [92]
VSV +   [93]
Melanoma Ad   TR/TERT [44]
Mesothelioma MV +   [94]
Colon cancer Ad   CMV [95]
Ad   CMV/CEA [96]
Lentivirus   UbC [97]
Lentivirus + UbC [98]
Ad + CMV [99]
Ad   TERT, TR [44]
MV +   [100]
Colorectal cancer Ad + Wnt-responsiveTCF4 [101]
Ad + TR [102]
Hepatoma Ad   HIP [103]
Plasmid   AFP [104]
Retrovirus + CMV [105]
Retrovirus + TERT [106]
  Plasmid-polyplex   CMV [107]
NIS-MSC   CMV in MSC [108]
PAMAM-Ad   CMV [109]
Pancreatic cancer Ad   MUC1 [110]
MV +   [111]
Ad + E3 [82]
  Ad   Survivin [112]
Cervical cancer Retrovirus + CMV [105]
  1. (*): to enhance the tumor growth inhibition; (**): tumor cells-specific promoter.
  2. Abbreviations: polyplex synthetic polymeric vector, CMV cytomegalovirus, MV measles virus, Ad adenovirus, LTR long terminal repeat, VSV vesicular stomatitis virus, TR telomerase RNA, TERT telomerase reverse transcriptase, CEA carcinoembryonic antigen, UbC ubiquitin C, Wnt Wingless-related integration site, TCF4 transcription factor 4, PAMAM-Ad adenoviral vectors after coating with synthetic poly(amidoamine) dendrimers, HIP hepatocarcinoma-intestine-pancreas gene, AFP alpha-fetoprotein, MSC mesenchymal stem cells, MUC1 mucin1 gene, E3 E3 antigen.